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Aims T lymphocytes play an important role in atherosclerosis development, but the role of the CD8þ T-cell remains
debated, especially in the clinically relevant advanced stages of atherosclerosis development. Here, we set out to




Human endarterectomy samples analysed by flow cytometry showed a negative correlation between the percent-
age of CD8þ T-cells and macrophages, suggesting a possible protective role for these cells in lesion development.
To further test this hypothesis, LDLr-/- mice were fed a western-type diet (WTD) for 10 weeks to induce
atherosclerosis, after which they received CD8a-depleting or isotype control antibody for 6 weeks. Depletion of
CD8þ T-cells in advanced atherosclerosis resulted in less stable lesions, with significantly reduced collagen content
in the trivalve area, increased macrophage content and increased necrotic core area compared with controls.
Mechanistically, we observed that CD8 depletion specifically increased the fraction of Th1 CD4þ T-cells in the
lesions. Treatment of WTD-fed LDLr-/- mice with a FasL-neutralizing antibody resulted in similar changes in macro-
phages and CD4þ T-cell skewing as CD8þ T-cell depletion.
....................................................................................................................................................................................................
Conclusion These findings demonstrate for the first time a local, protective role for CD8þ T-cells in advanced atherosclerosis,
through limiting accumulation of Th1 cells and macrophages, identifying a novel regulatory mechanism for these
cells in atherosclerosis.
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1. Introduction
Atherosclerosis is a chronic disorder characterized by inflammation and
accumulation of lipids in the vessel wall. Inflammation plays a key role
throughout all stages of atherosclerosis development, involving a com-
plex interplay between different inflammatory cell types. Among these
are CD8þ T-cells, which could play an important role in all stages of ath-
erogenesis, as they represent 29% of all leucocytes in early human
lesions, increasing to 50% in advanced plaques.1 In accordance, CD8þ T-
cell numbers are shown to increase significantly as human lesions be-
come more progressed and vulnerable to rupture but show a decrease
in healed plaque ruptures and fibrotic calcified plaques.2 Also in the cir-
culation, CD8þ T-cells have been linked to atherosclerosis development
as the percentage of low-differentiated CD8þCCR7þCD45RAþ T-cells
is reduced in patients with advanced coronary atherosclerosis compared
with those without significant coronary disease.3 Furthermore, a signifi-
cant correlation between the total number of CD8þ T-cells in the circu-
lation and the occurrence of myocardial infarction was established,4
suggesting that CD8þ T-cells contribute to lesion growth and instability.
Interestingly, the same study demonstrates an inverse correlation be-
tween the number of IFN-cþCD8þ T-cells and carotid stenosis, suggest-
ing that certain CD8þ T-cell subpopulations slow down lesion
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progression. The PD-1þTIM-3þCD8þ T-cell subset has been identified
in the circulation of atherosclerotic patients, which exhibit an increased
production of anti-atherogenic cytokines and decreased pro-
atherogenic cytokines, suggesting a regulatory function for these cells in
atherogenesis.5
Several studies in experimental models of atherosclerosis have been
conducted to provide insight into the role of CD8þ T-cells in atherogen-
esis, but the results are thus far conflicting.6–12 Whereas CD8þ T-cells
can induce lesion growth and instability, through lysis of endothelial cells
and vascular smooth muscle cells,9 CD8þ T-cell mediated killing of den-
dritic cells and follicular helper T-cells can reduce plaque formation.11,12
Importantly, studies in murine atherosclerotic models focus mainly on
initial lesion development, whereas it is clinically more relevant to study
advanced and/or unstable lesions, as patients usually experience symp-
toms related to severe stenosis when lesions are advanced. Therefore,
from a drug development perspective, it is most valuable to understand
the role of CD8þ T-cells in this stage of disease progression, as this is the
stage when pharmacological intervention is possible.
In this study, we aimed to assess how CD8þ T-cells affect plaque com-
position and stability of advanced lesions. We show a negative correla-
tion between the percentage of CD8þ T-cells and macrophages in
human endarterectomy samples, suggesting a possible protective role
for CD8þ T-cells in the more advanced stages of atherogenesis.
We next set out to investigate the role of CD8þ T-cells in advanced pla-
ques by CD8þ T-cell depletion in the low-density lipoprotein receptor
(LDLr) knockout mouse model. We show here for the first time that
CD8þ T-cells contribute to increased plaque stability, as well as to a
microenvironment-specific skewing of CD4þ T-cells within the lesions.
2. Methods
2.1 Human studies
Seven plaques from the carotid artery and 12 plaques from the femoral
artery were obtained during endarterectomy from anonymous individu-
als, from whom we did not receive any patient details. The patients
underwent endarterectomy surgery between July and December 2016
at the Haaglanden Medical Center, Westeinde, The Hague, Netherlands.
The handling of all human samples complied with the ‘Code for Proper
Secondary Use of Human Tissue’ and conforms with the principles out-
lined in the Declaration of Helsinki. Single-cell suspensions were
obtained from human plaques by cutting the tissue into small pieces, fol-
lowed by a 2-h digestion at 37C with an enzymatic mix consisting of col-
lagenase IV (Gibco) and DNase (Sigma) as previously described.13 Cells
were stained for flow cytometric analysis as described below.
2.2 Animals
LDLr-/- and apolipoprotein E (ApoE)-/- mice were purchased from
Jackson Laboratory (Sacramento, CA, USA) and bred in-house. Animals
were kept under standard laboratory conditions; food and water were
provided ad libitum. All animal work was performed in compliance with
the Dutch government guidelines and the Directive 2010/63/EU of the
European Parliament. Experiments were approved by the Ethics
Committee for Animal Experiments of Leiden University.
2.3 Murine studies
For the pilot study to determine the dosing regimen of the CD8a-deplet-
ing antibody, male LDLr-/- mice (n = 3) were injected with 50lg anti-
CD8a antibody (clone 2.43, BioXcell, NH, USA). A 100lL of blood was
drawn for a baseline measurement and at 1, 4, and 7 days post-injection
from the tail vein in EDTA containing tubes (Sarstedt) and subsequently
analysed by flow cytometry. For the CD8 depletion study, male LDLr-/-
mice (n = 24) were fed a western-type diet (WTD) containing 0.25% cho-
lesterol and 15% cocoa butter (Special Diet Services, Witham, Essex, UK)
for 10 weeks, and subsequently randomized into two groups based on
age, weight, and plasma cholesterol levels. WTD feeding was continued
for another 6 weeks combined with twice weekly i.p. injections of 50lg
rat IgG2b isotype control (clone LTF-2) or anti-CD8a antibody. During
the 6-week injection period, depletion efficiency was monitored by draw-
ing 100lL of blood from the tail vein in EDTA containing tubes (Sarstedt)
from n = 6 mice per group every 2 weeks the day after injection, alternat-
ing each week between the mice. At the end of the experiment, mice
were sacrificed via subcutaneous injection with a mix of ketamine
(100 mg/mL), sedazine (25 mg/mL) and atropine (0.5 mg/mL) and tissues
were harvested after in situ perfusion using PBS. Total cholesterol levels
were assessed using an enzymatic colorimetric assay (Roche Diagnostics).
To investigate FasL expression on CD8þ T-cells of atherosclerotic mice,
three male ApoE-/- mice of 65 weeks old were used, which display advanced
atherosclerotic lesions at this age. Mice were sacrificed and spleens and aor-
tas were harvested after in situ perfusion with PBS.
For the FasL blocking study, male LDLr-/- mice (n = 20) were fed a
WTD for 12 weeks, and subsequently randomized into two groups based
on age, weight, and plasma cholesterol levels. WTD feeding was continued
for 2 weeks combined with i.p. injections on alternate days of 500lg FasL-
neutralizing antibody (clone MFL414) or Armenian hamster isotype control
(Innovative Research, MI, USA). After a total of eight injections, mice were
sacrificed, and tissues were harvested after in situ perfusion with PBS.
2.4 Cell preparation and flow cytometry
Mice were sacrificed and blood, spleens, and aortas were harvested.
WBCs were obtained by lysing the blood twice for 2 min with lysis buffer
(0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA; pH 7.3). Single-cell
suspensions of spleens were obtained by using a 70-lm cell strainer
(Greiner Bio-One). Splenocytes were lysed for 1 min with lysis buffer to
obtain WBCs. Aortas were cleaned of perivascular fat and cut up into
small pieces and digested by incubation with digestion mix (collagenase I
450 U/mL, collagenase XI 250 U/mL, DNAse 120 U/mL, and hyaluroni-
dase 120 U/mL; all Sigma-Aldrich) for 30 min at 37C, while shaking and
subsequently strained over a 70-lm strainer. A maximum of 200 000
cells was stained with the appropriate antibodies (Supplementary mate-
rial online, Table SI). To stain apoptotic cells, Annexin V Apoptosis
Detection Kit (eBioscience) was used according to manufacturer’s proto-
col. For intracellular staining, cells were fixed and permeabilized by using
an intracellular staining kit (eBioscience) according to manufacturer’s pro-
tocol. Flow cytometry analyses were performed on a Beckman Coulter
Cytoflex S or BD Biosciences Canto II and FlowJo software (Treestar).
2.5 Histological analysis
All hearts were embedded in O.C.T. compound (Sakura) and sectioned
horizontally to the aortic axis and towards the aortic arch. Upon identifi-
cation of the aortic root, defined by the trivalve leaflets, 10 lm sections
were collected. Analysis of lesion size was performed on cryosections of
the aortic root lesion stained with Oil-red O and haematoxylin
(Sigma-Aldrich). Corresponding sections were stained with Sirius Red
(Sigma-Aldrich) to determine collagen content and with Masson’s
Trichrome staining (Sigma-Aldrich) to determine the necrotic area.
Plaque macrophages were stained immunohistochemically by using a
monocyte/macrophage (MOMA)-2 antibody (1:1000 rat IgG2b, Serotec
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Ltd.) as a primary antibody, goat anti-rat IgG alkaline phosphatase conju-
gate (1:100; Sigma-Aldrich) as a secondary antibody, and nitro blue tetra-
zolium and 5-bromo-4-chloro-3-indolyl phosphate as enzyme
substrates. Furthermore, sections were stained with an antibody against
CD4 (1:90 clone RM4-5, BD Biosciences), biotinylated rabbit anti-rat
IgG (1:200, Vector) as a secondary antibody, and 3-amino-9-ethyl carba-
zole (Dako) for visualization. For VCAM-1 staining, sections were incu-
bated with CD106 antibody (1:100, BD Biosciences), followed by
incubation with biotinylated rabbit anti-rat IgG (1:200, Vector) as a sec-
ondary antibody, and stained with 3-amino-9-ethyl carbazole (Dako).
TUNEL staining was performed using the In Situ Cell Death Detection
Kit, POD (Sigma-Aldrich). The average plaque size (in lm2) was calcu-
lated from five sequential sections. For all other stainings, three subse-
quent sections displaying the highest plaque content per mouse were
analysed. All microscopic analyses were performed on a Leica DM-RE
microscope using Leica QWin software and were blinded for indepen-
dent analysis. The percentages of collagen, VCAM-1þ cells, and macro-
phages in the atherosclerotic lesions were determined by dividing the
area in lm2 stained positive for collagen, VCAM-1 or MOMA-2 by the
total lesion surface area, and calculated as a percentage. The percentage
of necrosis was determined by dividing the acellular area by the total le-
sion surface area and again calculated as a percentage. The total number
of CD4þ T-cells or TUNELþ cells in each stained section were counted,
and the average was divided by the total lesion surface area in order to
obtain the number of TUNELþ or CD4þ T-cells per mm2 of lesion area.
2.6 Cell culture
CD4þ and CD8þ T-cells were isolated from splenocytes of a male LDLr-/-
mouse of 18 weeks old using the CD4þ and CD8þ T-cell isolation kits
(Miltenyi Biotec). Isolated cells were mixed in a 1:1 ratio and 0.5*106 total
cells were plated out in 12-well plates (Greiner Bio-One) and cultured
overnight at 37C and 5% CO2 in RPMI 1640 medium containing 25 mM
HEPES (Lonza) supplemented with 10% foetal calf serum (FCS), 60lM
b-mercaptoethanol (Sigma), 100 U/mL mix of penicillin/streptomycin
(PAA), 1% non-essential amino acids (NEAA; Gibco), 1% sodium pyruvate
(Sigma), and 2% L-glutamine (Lonza). The medium was supplemented with
1lg/mL of anti-CD3 and anti-CD28 (ThermoScientific) and 10lg/mL of
either FasL-neutralizing antibody (clone MFL414) or Armenian hamster iso-
type control (Innovative Research, MI, USA).
2.7 Statistical analysis
Data are presented as individual dot plots with bars denoting the mean,
the number of animals in each group is stated in the text. Data were
tested for normal distribution and analysed by using a two-way ANOVA,
two-tailed Student’s t-test, or Mann–Whitney test, as appropriate.
Statistical analysis was performed by using Prism (GraphPad). Probability
values of P < 0.05 were considered significant.
3. Results
3.1 CD8þ T-cell content negatively
correlates with macrophage content in
human atherosclerosis
With the progression of atherosclerosis, the total number of CD8þ
T-cells in the plaque increases.2 However, other leucocyte populations
may also increase in number. We sought to investigate whether there is
a correlation between the number of these CD8þ T-cells and other
atherogenic cell types in human atherosclerosis. Nineteen endarterec-
tomy samples were obtained from atherosclerosis patients and analysed
by flow cytometry for CD8þ T-cells, CD4þ T-cells, and macrophages
(Figure 1A–C, for gating strategy, see Supplementary material online,
Figure S1). Interestingly, there was a significant inverse correlation be-
tween the percentage of CD8þ T-cells and macrophages (P = 0.03,
Figure 1D), which could indicate that CD8þ T-cells limit macrophage
content in human atherosclerosis. Importantly, this correlation was not
observed between the percentage of CD4þ T-cells and macrophages
(Figure 1E), suggesting that a change in macrophage content does not
lead to an increase in every T-cell subset and the correlation between
CD8þ T-cells and macrophages may have functional relevance.
3.2 Lesion size is not affected by CD8þ
T-cell depletion in advanced stages of
murine atherosclerosis
To further elucidate the role of CD8þ T-cells in advanced atherosclero-
sis, we fed LDLr-/- mice a WTD for 10 weeks to establish lesions, fol-
lowed by another 6 weeks of WTD combined with twice weekly
administration of a CD8a-depleting antibody or an isotype control anti-
body (see Supplementary material online, Figure S2A for the experimen-
tal setup). The dosing regimen was determined by a pilot experiment, in
which 3 LDLr-/- mice were injected with 50lg of CD8a-depleting anti-
body. CD8þ T-cells were fully depleted for at least 4 days
(Supplementary material online, Figure S2B). As a slight increase in the
number of CD8þ T-cells 7 days after injection of the anti-CD8 monoclo-
nal antibody was observed, the mice in the atherosclerosis experiment
were treated twice weekly. Administration of the CD8 depleting anti-
body in the atherosclerosis study resulted in successful depletion of
CD8þ T-cells in blood throughout the course of the experiment
(Supplementary material online, Figure S2C). At sacrifice, successful de-
pletion was also observed in the spleen and aorta, whereas the CD8aþ
dendritic cell population in the spleen was only slightly affected
(Supplementary material online, Figure S2D and E). We observed no dif-
ferences in the percentages of NK cells, neutrophils, or monocytes in
the blood at sacrifice (Supplementary material online, Figure S2F–H).
Upon treatment with the CD8-depleting antibody, we did observe a per-
centual increase in CD4þ T-cells and B-cells in the spleen, however, the
absolute numbers of these cells were not different upon treatment
(Supplementary material online, Figure S2I–L). Depletion of CD8þ T-cells
in advanced atherosclerosis did not affect the aortic root lesion size as
determined by Oil-red O staining (Figure 2). We found no difference in
body weight at any time during the treatment, nor did we find any differ-
ences in serum cholesterol levels (Supplementary material online, Figure
S2M and N).
3.3 Advanced atherosclerotic lesions show
decreased plaque stability upon CD8þ T-
cell depletion and increased inflammatory
CD4þ T-cells responses
Although lesion size was not significantly affected by CD8þ T-cell deple-
tion in advanced atherosclerosis, we investigated whether plaque stabil-
ity and composition were altered in the aortic root lesions of these mice.
The collagen content, assessed by Sirius Red staining, showed a signifi-
cant decrease of 18% upon depletion of CD8þ T-cells (P = 0.02, Figure
3A and B). In addition, we found a 42% increase in necrotic core forma-
tion in the CD8þ T-cell depleted group (P = 0.04, Figure 3C and D). The
content of total apoptotic cells in the lesions was not significantly
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Figure 1 Inverse correlation between the percentages of CD8þ T cells and macrophages in human atherosclerotic lesions. Flow cytometry analysis of
(A) CD8þ T cells (B) CD4þ T cells, and (C) macrophages in endarterectomy samples from the arteria carotis (n = 7, open circles) or arteria femoralis
(n = 12, closed circles) expressed as a percentage of live CD45þ cells. Cells were gated as shown in Supplementary material online, Figure S1.
(D) Correlation between the percentage of CD8þ T cells and macrophages in all endarterectomy samples. (E) Correlation between the percentage of
CD4þ T cells and macrophages in all endarterectomy samples. Significance was determined using linear regression analysis.
Figure 2 CD8þ T-cell depletion does not affect lesion size in advanced atherosclerosis. (A) Quantification of lesion size in the aortic roots of LDLr-/-
mice treated with CD8-depleting or isotype antibody by Oil-red O staining, n = 12 mice per group. Significance was determined using an unpaired t-test.
(B) Representative images of ORO staining.
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different between both groups, as measured by TUNEL staining
(P = 0.48, Supplementary material online, Figure S3A). Regarding the
MOMA positive area, we observed a 27% increase upon CD8þ T-cell
depletion in the total area stained positive for MOMA-2 (P = 0.045,
Figure 3E and F). The most likely reasons for the increasing number of
macrophages and decreased stability of the lesions after CD8þ T-cell de-
pletion would be an enhanced influx of monocytes or reduced cell death
of macrophages in the lesion. Regarding monocyte influx, VCAM-1 is
known to play an important role in monocyte adhesion upon the endo-
thelium of the atherosclerotic lesion.15 However, the expression of
Figure 3 CD8þ T-cell depletion in advanced lesions reduces plaque stability and increases necrosis and macrophage content. (A) Quantification of col-
lagen content by Sirius Red staining in the aortic roots of LDLr-/- mice treated with CD8-depleting or isotype antibody. Significance was determined using
a Mann–Whitney test. (B) Representative images of Sirius Red staining. (C) Quantification of necrosis in the aortic roots of the LDLr-/- mice. Significance
was determined using an unpaired t-test. (D) Representative images of the Masson’s Trichrome staining, necrotic areas are indicated by arrows. (E)
Macrophage quantification in the aortic roots of the LDLr-/- mice. (F) Representative images of MOMA-2 staining, n = 12 mice per group. Significance was
determined using an unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001.
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VCAM-1 in the aortic root endothelium was not found to be significantly
different between both groups (P = 0.14, Supplementary material online,
Figure S3B). Furthermore, the percentage of monocytes in the blood did
not show any differences between the two groups (P = 0.86,
Supplementary material online, Figure S3C). Based on these results, we
cannot exclude effects of CD8þ T-cell depletion on macrophage recruit-
ment or adhesion. However, it is likely that other, lesion localized, mech-
anisms may be involved in the observed increase in lesional macrophage
content.
Besides macrophages and CD8þ T-cells, CD4þ T-cells represent a
third major leucocyte population in atherosclerotic lesions. Especially,
IFN-c-producing Th1 cells have been associated with macrophage acti-
vation and plaque instability.16 To determine whether CD4þ T-cells play
a role in destabilizing the plaques upon depletion of CD8þ T-cells, we
analysed the presence and phenotype of CD4þ T-cells in the lesions.
We observed no difference in the number of CD4þ T-cells in the aortic
root lesions of these mice by immunohistochemistry (P = 0.44,
Figure 4A). However, we observed a skewing towards a more inflamma-
tory Th1 phenotype in the aortic plaques of the CD8-depleted mice
compared with the controls. The T-bet expression in CD4þ T-cells in
this group was significantly increased by 25% resulting in an over two-
fold increase in the T-bet/GATA3 ratio (P = 0.01, Figure 4B,
Supplementary material online, Figure S3D), indicating a shift from the
Th2 towards the Th1 phenotype. Interestingly, this skewing of CD4þ T-
cell responses was not observed in the circulation (data not shown),
whereas opposite trends were observed for T-bet expression (P = 0.02)
and the T-bet/GATA3 ratio in the splenic compartment (P = 0.09,
Figure 4C, Supplementary material online, Figure S3D). Total CD4þ T-cell
numbers in the spleen were not significantly different between both
treatment groups (P = 0.15, Figure 4D). Taken together, these results sug-
gest a local, anti-inflammatory, and lesion-stabilizing role of CD8þ T-cells
in advanced atherosclerosis.
3.4 FasL blockade increases inflammation
in advanced atherosclerotic lesions
Although CD8þ T-cells are foremost known as a pro-inflammatory cell
type, various reports also support an immune regulatory role for these
cells.11,12,17 For instance, CD8þ T-cells can kill dendritic cells in an
antigen-specific, perforin-dependent manner18 and can regulate T-cell
homeostasis by killing activated T-cells via a Fas-FasL-mediated mecha-
nism.19 Interestingly, a deficiency in Fas on haematopoietic cells in
LDLr-/- mice results in an enhanced inflammatory state20 and a decrease
in lesion stability,21 suggesting Fas-FasL interaction is an important im-
mune regulatory pathway in the context of hypercholesteremia. As Th1
cells are more susceptible to FasL-induced apoptosis than Th2 cells,22
we hypothesized that the Th1 skewing effect we observed specifically in
the lesions of CD8þ T-cell depleted mice, was in part mediated through
the lack of FasL-induced apoptosis. Therefore, we first set out to deter-
mine whether CD8þ T-cells in the lesions of advanced atherosclerotic
mice express increased levels of FasL compared with their counterparts
in the spleen. To this end, we isolated the spleens and aortas of mice
with advanced atherosclerosis. Flow cytometry analysis confirmed that
the mean fluorescence intensity for FasL was 1.7-fold higher in the aortas
compared with the spleens (P = 0.008, Figure 5A, Supplementary material
online, Figure S4A). To assess whether FasL-mediated killing by CD8þ T-
cells specifically affects the Th1 CD4þ T-cells in our model, CD8þ and
CD4þ T-cells from LDLr-/- mice were isolated and stimulated in vitro in
the presence of a blocking anti-FasL antibody or isotype control antibody
and stained for apoptosis using Annexin V. Whereas apoptosis de-
creased only slightly and not significantly in Th2 cells upon anti-FasL
treatment (1.5 fold, P = 0.07, Figure 5B), there is a striking 4.1-fold de-
crease in apoptotic Th1 cells (P = 0.0001, Figure 5C, Supplementary mate-
rial online, Figure S4B). This confirms previous work22 and shows that
FasL expressed on CD8þ T-cells preferentially targets Th1 cells for apo-
ptosis. Finally, we proceeded to block FasL activation in LDLr-/- mice in
an advanced stage of lesion formation in order to assess whether this af-
fected the CD4þ T-cell responses and lesion development in a similar
fashion as CD8þ T-cell depletion. In agreement with the CD8þ T-cell
depletion study, treatment with anti-FasL antibody resulted in a signifi-
cant increase in T-bet-expressing CD4þ T-cells in the aortic lesion
(P = 0.04, Figure 5D) and not in the spleen (Supplementary material on-
line, Figure S4C), although GATA3 expressing CD4þ T-cells were not
changed (P = 0.98, Figure 5E, Supplementary material online, Figure S4D).
We did observe a small, non-significant 1.3-fold increase in the T-bet/
GATA3 ratio in the aortas of the treated mice (P = 0.29, Figure 5F).
Moreover, in agreement with the CD8þ T-cell depletion study, we ob-
served no changes in lesion size (P = 0.09, Figure 5G), but immunohisto-
chemical analysis of the aortic root lesions revealed a 69% increase in
the MOMA-2 positive area upon treatment with the anti-FasL antibody
(P = 0.04, Figure 5H). Together, these data suggest that FasL-mediated
interactions play an important immune regulatory role in atherosclerosis
by decreasing Th1 CD4þ T-cells and macrophages within the lesion.
4. Discussion
In this study, we show that CD8þ T-cells may be protective in advanced
stages of atherosclerotic lesion development. The negative correlation,
we observed between the percentages of CD8þ T-cells and macro-
phages in human atherosclerosis indicates that CD8þ T-cells may play a
protective role by reducing plaque macrophage content. Additionally, in
a murine model, we show that CD8þ T-cells contribute to increased pla-
que stability in advanced atherosclerotic lesions, by restricting the accu-
mulation of macrophages and pro-inflammatory Th1 cells. Importantly,
we show that the effect of CD8þ T-cells on Th1 cells is specific to the
microenvironment of the lesion, as such effects are not observed in
splenic tissue. Our results are in agreement with previously published
studies, demonstrating that antigen-specific CD8þ cells are protective
against atherosclerosis by mounting a cytolytic response against antigen-
presenting dendritic cells.11,23 Previous studies have shown that
ApoE-/-CD8-/- mice show no difference in early or late atherosclerotic
lesion development compared with ApoE-/- mice.6 Additionally, full body
knockout of the antigen peptide transporter TAP1 in ApoE-/- mice,
resulting in deficient MHC-I antigen presentation, did not affect lesion
development at either early or late stages of atherosclerosis.7 However,
these mutations are able to affect other cell types besides CD8þ T-cells,
and therefore, do not provide conclusive evidence about CD8þ T-cell
function in atherogenesis. Other work has shown pro-atherogenic roles
for CD8þ T-cells in atherosclerosis, based on reduced monopoiesis in
the absence of CD8þ T-cells.8 In contrast to the data presented here,
however, the aforementioned study focused on early stages of athero-
sclerotic lesion development, which suggests the role of CD8þ T-cells
may depend on the stage of atherogenesis. Indeed, another study investi-
gating CD8a- and CD8b-depletion on initial lesion development in
ApoE-/- mice also showed reductions in lesion area, macrophage accu-
mulation and necrotic core formation.9 Together, this indicates a pro-
atherogenic role for CD8þ T-cells in initial atherosclerosis, whereas our
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data suggest a protective role for these cells in advanced atherosclerosis.
In agreement with our findings, C57BL/6J mice that are deficient for
MHC class I demonstrated a three-fold increase in atherosclerotic lesion
area compared with WT mice after 15 weeks on an atherogenic diet,10
suggesting a protective role for CD8þ T-cells. Several regulatory CD8þ
T-cell subsets have been described that could exert protective effects
on lesion development,12,17 but as we used a CD8a-depleting antibody,
we depleted all CD8þ T-cell subsets and were therefore unable to iden-
tify which CD8þ T-cell subset is responsible for the protective effects
observed here.
Figure 4 CD8þ T-cell depletion in advanced lesions skews CD4þ T-cell responses towards a more inflammatory phenotype specifically in the aortic
microenvironment. (A) Quantification of CD4þ T-cell staining per mm2 of lesion in the aortic roots of LDLr-/- mice treated with CD8-depleting or isotype
antibody, and representative images of the CD4 staining, arrows indicate CD4þ cells. (B) Flow cytometry analysis of percentages of aortic CD4þ T-cells
expressing GATA3 and T-bet, as well as the T-betþ/GATA3þ ratio. (C) Flow cytometry analysis of the percentages of splenic CD4þ T-cells expressing T-
bet, as well as the T-betþ/GATA3þ ratio. (D) The total amount of CD4þ T-cells in the spleens at the time of sacrifice. Cells were pregated on Live
Thy1.2þCD4þ cells, n = 12 mice per group. All significance was determined using unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001.
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..The lesion size in advanced stages of atherosclerosis was not affected
by CD8þ T-cell depletion in our study. As we only started depleting the
CD8þ T-cells after 10 weeks of WTD feeding, upon which lesions are al-
ready established, we expected the treatment to mainly affect lesion
composition. Indeed, we did observe a decreased plaque stability upon
depletion in this stage. Specifically, CD8þ T-cell depletion decreased
collagen content, whereas it increased necrotic core formation and pla-
que macrophages. We observed a microenvironment-specific skewing
of CD4þ T-cells towards the Th1 phenotype, which may explain the ob-
served effects on plaque stability. Th1 cells are known to produce high
levels of IFN-c, which has been shown to inhibit collagen synthesis by
vascular smooth muscle cells24 and may explain the reduced collagen
Figure 5 FasL blockade preferentially inhibits apoptosis of Th1 compared with Th2 CD4þ T-cells and increases inflammatory CD4þ T-cell responses
in advanced atherosclerosis. (A) Flow cytometry analysis of FasL mean fluorescence intensity on CD8þ T cells in single-cell suspensions obtained from
the indicated organs of three male ApoE-/- mice of 65 weeks old. (B and C) LDLr-/- derived CD4þ and CD8þ T-cells were cultured in a 1:1 ratio for 24 h
and stimulated with anti-CD3 and anti-CD28 antibodies in the presence of either anti-FasL or isotype antibody. Flow cytometry analysis of Annexin V
staining on Thy1.2þCD4þGATA3þ (B) and Thy1.2þCD4þT-betþ (C) cells, n = 4. (D–F) Flow cytometry analysis of aortic cells derived from LDLr-/- mice
treated with anti-FasL or isotype antibody. Percentages of aortic CD4þ T-cells expressing T-bet (D), GATA3 (E), as well as the T-betþ/GATA3þ (F) ratio.
Cells were pregated on Live Thy1.2þCD4þ cells. (G) Quantification of lesion size in the aortic roots of the LDLr-/- mice treated with anti-FasL or isotype
antibody by Oil-red O staining. (H) Macrophage quantification in the aortic roots of the LDLr-/- mice, n = 9 in aFASL group, n = 8 in isotype group. All sig-
nificance was determined using unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001.
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content observed here. Indeed, vaccination against IL-12, a cytokine
known to favour the development of Th1 cells, was previously shown to
inhibit atherosclerosis development and promote lesion stability via a
Th1/Th2 switch and the associated reduction in IFN-c levels.25 A Th1
shift and an increase IFN-c may explain why we observed an increase in
plaque resident macrophages upon CD8 depletion. Monocyte transmi-
gration into atherosclerotic lesions is mediated by up-regulation of IFN-c
inducible VCAM-1 and ICAM-1.26 Even though we found no increases in
VCAM-1 expression at the moment of sacrifice, we cannot exclude reg-
ulation of these adhesion molecules at earlier time points during the ex-
periment. Furthermore, we have not measured ICAM-1 expression,
which may have contributed to the increased MOMA-2 staining ob-
served in this study. Alternatively, the increased macrophage accumula-
tion may be caused by decreased apoptosis of macrophages, however,
we did not observe any changes in the number apoptotic (TUNELþ)
cells in lesions of CD8þ T-cell depleted mice. Importantly, we provide
data suggesting a direct role of CD8þ T-cells in the regulation of Th1
CD4þ T-cells and macrophages through Fas-FasL-mediated apoptosis.
Fas-FasL interaction is a major contributor to apoptosis of activated
CD4þ T-cells, a process referred to as activation-induced cell death.27
We propose that FasLþCD8þ T-cells may be able to regulate CD4þ T-
cell responses via Fas-FasL-induced apoptosis of Th1 cells. Fas expres-
sion on bone marrow-derived cells has been shown to play a protective
role in atherosclerosis development as bone marrow transplantation of
cells derived from Fas-mutant lpr mice into LDLr-/- mice resulted in less
fibrous lesions compared with transplantation with WT bone marrow,
suggesting Fas expression contributes to a more stable lesion pheno-
type.21 Here, we show that CD8þ T-cells within atherosclerotic lesions
express higher levels of FasL than their counterparts in the spleen, sug-
gesting that the atherosclerotic microenvironment may affect CD8þ T-
cell phenotype and function. Th1 cells have an increased susceptibility to
FasL-induced cell death, as they express lower levels of Fas-associated
phosphatase 1, which plays an important role in inhibiting FasL-induced
cell death by attenuating Fas export to the cell surface.22,28 Indeed, we
observed that upon in vitro treatment of activated LDLr-/- derived CD4þ
and CD8þ T-cells with a FasL-neutralizing antibody, the decrease in apo-
ptotic cells was much larger in the Th1 subset compared with the Th2
subset. Upon in vivo treatment of atherosclerotic mice with a neutralizing
FasL antibody, we observed a similar skewing of CD4þ T-cell subsets in
favour of Th1 CD4þ T-cells as we did in CD8-depleted mice. Although
this in vivo experiment cannot rule out contributions of other FasLþ cell
types; in light of the up-regulation of FasL on CD8þ T-cells and the in-
creased susceptibility of Th1 cells to FasL-induced cell death these data
suggest that FasL is an important effector molecule for CD8þ T-cells to
limit Th1 accumulation in the plaque.
Alternatively to direct CD4þ T-cell inhibition, indirect effects on
CD4þ T-cell skewing can be exerted via cytolytic killing of macrophages
by CD8þ T-cells. Inflammatory macrophages are known to secrete cyto-
kines that can recruit CD4þ T-cells towards the lesion site and skew
them towards the Th1 phenotype.29,30 CD8þ T-cells have long been
established to have the capacity to kill virus- or bacteria-infected
APCs.31 Inflammatory stimuli such as IFN-c are able to increase Fas ex-
pression on cultured macrophages, which increases their susceptibility
to Fas-mediated apoptosis.32 Additionally, free cholesterol loading in
WT macrophages was previously shown to result in caspase-induced ap-
optosis, which is much less pronounced in either gld or lpr macro-
phages.33 This suggests that macrophage foam cells could be killed by
CD8þ T-cells in a Fas-FasL mediated fashion. As CD8þ T-cell depletion
in our study resulted in an increased lesional macrophage content,
CD8þ T-cells could potentially regulate lipid-loaded macrophage num-
bers in advanced atherosclerosis directly. Interestingly, upon treatment
with an anti-FasL antibody, we observed an increase in lesion macro-
phage content as well, suggesting that FasL-induced apoptosis of macro-
phages by CD8þ T-cells may contribute to their protective effect against
atherosclerosis. Notably, we observed a link between CD8þ T-cell per-
centages and the percentage of macrophages in human lesions, suggest-
ing that the regulatory role of CD8þ T-cells we describe here for a
murine model of atherosclerosis, may hold true in humans as well.
Finally, our results indicate a microenvironment-specific role of CD8þ
T-cells in controlling Th1 responses in atherosclerotic lesions, as we ob-
served this effect only in the aorta and not in the blood or spleen. This find-
ing illustrates the importance of investigating local immune responses, in
addition to systemic immune responses. We hypothesize that the athero-
sclerotic microenvironment contains many lipid-derived and inflammatory
stimuli that alter the CD8þ T-cell phenotype specifically at this site. A re-
cent clinical trial with IL-1b-neutralizing antibodies (canakinumab) showed
that systemic anti-inflammatory responses significantly reduce cardiovascu-
lar events,34 although administration of this drug could also cause neutro-
penia and was associated with fatal infection. As the anti-inflammatory
effect of CD8þ T-cells appears to act locally, expanding these T-cells may
provide an interesting strategy to lower inflammation associated with ath-
erosclerosis without unwanted systemic immune suppression.
5. Conclusion
In conclusion, these in vivo experiments demonstrate a protective effect
of CD8þ T-cells in advanced atherosclerotic lesions via a reduction of
macrophages and Th1 cells and show an immune modulatory role for
FasL. The protective effect of CD8þ T-cells may be exploited by stimu-
lating CD8þ T-cell responses in advanced stages of atherogenesis, which
could translate into the suppression of atherosclerosis in humans.
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